NetScientific PLC - Positive new data demonstrates NEATstiks potential
New data demonstrates NEATstik's potential as a rapid bacterial monitoring tool in lung disease
Published in the
"This encouraging data published in the renowned
The full text of the announcement released by ProAxsis can be found below.
Positive early data from the BRIDGE study, a three-year 1000+ patient study in bronchiectasis funded by the
The pan-EU study is exploring novel biomarkers to demonstrate what they can add to clinical practice. In the publication, the NEATstik® result has been correlated with the severity of lung disease, presence of bacterial infection and risk of future clinical worsening (exacerbations). Furthermore, NEATstik® was able to replicate the results of existing tests for chest infections in people with bronchiectasis within only ten minutes, providing a rapid sample-to-result test that can potentially support appropriate usage of antibiotic therapy. The study, led by Professor
The promising data on the performance of NEATstik® is announced for the first time in this publication and is the subject of a separate joint announcement from the BLF and the
Commenting on the publication, Dr
"We're delighted that NEATstik® has performed so effectively in this critically important study and we look forward to continuing to collaborate with this group of expert clinicians to maximise the availability of this novel test for centres caring for patients with chronic respiratory diseases."
Any queries concerning NEATstik®, or any requests for support with measuring other active protease biomarkers using the Company's proprietary ProteaseTag® technology, can be directed to [email protected]
For more information, please contact:
| || |
Tel: +44 (0)20 3514 1800
WHIreland (NOMAD, Financial Adviser and Broker)
Tel: +44 (0)20 7220 1666
For more information, please visit the website at www.NetScientific.net
ProAxsis is utilising its proprietary ProteaseTag® technology to develop a range of products for the measurement of active protease biomarkers of diseases. The company has already launched activity-based immunoassays for both neutrophil elastase and proteinase 3, as well as a rapid point-of-care test for neutrophil elastase (NEATstik®). ProteaseTags® provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.
ProAxsis is part of the
This announcement contains certain forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances. Actual outcomes and results may differ materially from any outcomes or results expressed or implied by such forward looking statements. Any forward-looking statements made by or on behalf of the Group are made in good faith based on the information available at the time the statement is made. No representation or warranty is given in relation to these forward-looking statements, including as to their completeness or accuracy or the basis on which they were prepared, and undue reliance should not be placed on them. The Group does not undertake to revise or update any forward-looking statement contained in this announcement to reflect any changes in its expectations with regard thereto or any new information or changes in events, conditions or circumstances, save as required by law and regulations. Nothing in this announcement should be construed as a profit forecast.
 The BRIDGE study - Bronchiectasis Research Involving Databases, Genomics and Endotyping to match the right treatment to the right patient.
 Shoemark et al (2019) ERJ
This information is provided by RNS, the news service of the
Quick facts: Netscientific PLC
Market Cap: £4.33 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE